Industry Trend Analysis - ADCs Will Sustain Interest As Positive Results Continue To Emerge - JAN 2018


BMI View: Antibody-drug conjugates will continue to gain attention as positive data are showcased at conferences. Small biotechs will remain as the primary developers of early stage compounds , with big pharma showing interest as compounds move to the later stages of development.

The AACR-NCI-EORTC symposium on molecular targets and cancer therapeutics, held in October, primarily focused on preclinical, early and mid-stage product candidates. Next-generation antibody-drug conjugates (ADC) were a key theme at the conference, highlighting a renewed interest as new ADCs gain approval. New approvals and late-stage trial data reflect that second-generation products are able to overcome the limitations of the first generation, and BMI previously noted that next-generation ADCs would generate interest in 2017 (see ' Second-Generation ADCs To Enter Market In 2017 ' , January 23 2017). While most of the ADC developments have been positive, there have been a few setbacks as not all compounds are successful in trials.

New ADCs Set To Enter The Clinic

This article is part of our Americas coverage. To access this article subscribe now or sign up for free trial